業績

2017年

新規抗腫瘍性化合物の開発

1. クルクミンアナログは ATP結合カセットトランスポーターのABCG2を介して抗がん剤の多剤耐性を解除する
   Murakami M, Ohnuma S, Fukuda M, Chufan EE, Kudoh K, Kanehara K, Sugisawa N, Ishida M, Naitoh T, Shibata H, Iwabuchi Y, Ambudkar SV, Unno M. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ABC transporter ABCG2：Drug Metabolism and Disposition September 2017: 45(11)

臨床研究

1. 心臓原発の肉腫症例の全ゲノム解析
   Yukinobu Ito, Daichi Maeda, Makoto Yoshida, Akihiko Yoshida, Yukitsugu Kudo-Asabe, Hiroshi Nanjyo, Chikako Izumi, Fumio Yamamoto, Masahiro Inoue, Hiroyuki Shibata, Hiroto Katoh, Shumpei Ishikawa, Hiromi Nakamura, Yasushi Totoki, Tatsuhiro Shibata, Shinichi Yachida, Akiteru Goto.Cardiac intimal sarcoma with PDGFRβ mutation and co-amplification of PDGFRα and MDM2: an autopsy case analyzed by whole-exome sequencing.Virchows Archiv,2017: 1-6.
2. 進行がん患者の低リン血症
   Taichi Yoshida, Daiki Taguchi, Koji Fukuda, Kazuhiro Shimazu, Masahiro Inoue, Katsunori Murata, Hiroyuki Shibata.Incidence of hypophosphatemia in advanced cancer patients: a recent report from a single institution.International journal of clinical oncology, 2017:22(2):244-249.
3. 抗PD-1抗体の早期胃癌に対する効果
   Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Masahiro Inoue, Hiroshi Nanjyo, Hiroyuki Shibata.Effect of anti-PD-1 antibody, nivolumab on early gastric cancer.International Cancer Conference Journal, 2017:1-6.